Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Certificates
A manufacturer’s certificate is a self-declaration. An accredited laboratory’s report is a third-party measurement. The trade prints both under one heading.
The last block on a properly built certificate is the part the trade ignores entirely, and it is the part that determines what the document is worth in an argument. Somebody performed the tests. Somebody reviewed the results. Somebody authorised the release of the batch on the strength of them. In a regulated plant those are distinct roles with distinct signatures and the separation is a control rather than a courtesy: the person who ran the assay does not get to decide unaided that the batch passes.
The bottom of a certificate carries the dates, the signatures and any boilerplate. A complete footer gives the date of manufacture, the date of analysis, and either a retest date or an expiry date with the convention named. It gives the name and role of the person who performed or compiled the testing, and separately of the person who reviewed and approved it. It states the storage conditions under which the stated properties hold. And it states, in a research-chemical context, the research-use-only restriction.
The two-signature convention is worth explaining because its absence is so universal here that its purpose is forgotten. Separating performance from approval is a control against a single person’s error or judgement determining a release. It is cheap, it requires no equipment, and it is the ordinary practice in every regulated laboratory. Its function is not ceremonial: it means that when a document turns out to be wrong, there is a record of who reviewed it and on what basis.
What the footer should not carry is a signature rendered as a reused image with no accompanying name. That is not evidence of anything improper on its own — scanned signature blocks are common in legitimate commerce — but it removes the one piece of information the block exists to supply, which is the identity of a person who can be asked.
An unsigned certificate is a statement with no author. It may be entirely accurate; it is simply not attributable, and attribution is most of what a release document does. The regulated convention of two signatures — one for the analyst who performed or compiled the work, one for the reviewer who approved its release — exists because release is a decision and decisions benefit from a second reader.
What the Journal looks for is narrower than a wet-ink signature, which nobody expects in a scanned document. We look for a name and a role. “Analysed by: L. Wen, Analytical Chemist. Approved by: Q. Zhang, QC Manager” is worth more than any flourish, because it identifies people who can be asked a question. A certificate signed with an illegible mark and no printed name has supplied the ceremony and withheld the content.
Of the twenty companies in the dossier programme, eleven print a name in the signature block, four print a role without a name, and five print neither. Two of the eleven print two names in the regulated pattern. These are documentary counts and nothing more; a company with no name on the certificate may have impeccable internal records, and several of them, when asked, produced signed internal release records promptly. The point is that a buyer cannot see any of that from the page.
The analytical work behind these products is often better than the paperwork that reports it.
On why a bad document is not a bad productAn accreditation logo on a letterhead means a body has assessed a laboratory against the international standard for testing competence and granted accreditation for a defined scope of methods. The scope is the part that matters and it is published: accreditation bodies maintain public registers listing, for each accredited laboratory, the tests and techniques covered. A laboratory can be validly accredited and the specific test on your certificate can lie outside its schedule.
Checking this takes a few minutes. Find the accreditation number on the document, look it up on the relevant national body’s register, and read the scope. What you are looking for is whether the technique used for your test — reversed-phase HPLC purity, mass spectrometric identity, water determination — appears. Where it does, the accreditation is doing work. Where it does not, the logo is a true statement about the laboratory and says nothing about the test in front of you.
The standard itself is clear that reports must identify what was and was not covered, and that accredited status attaches to activities rather than to organisations as a whole.1 The Journal makes this check on any certificate it intends to cite, and reports the result. It is the single most under-performed piece of due diligence in this market, principally because almost nobody knows the registers exist.
| Interval | Certificates | Share |
|---|---|---|
| Within 14 days | 31 | 49% |
| 15–60 days | 12 | 19% |
| 61–180 days | 5 | 8% |
| Over 180 days | 2 | 3% |
| One or both dates absent | 13 | 21% |
| Where only one date was present the certificate is counted in the final row. The median interval among the fifty documents carrying both dates was eleven days, which is unremarkable and reassuring; the more consequential interval — between the date of analysis and the date the buyer receives the vial — is not recorded on any certificate the Journal has seen. | ||
A manufacturer’s certificate of analysis and an independent laboratory’s test report are different instruments, and this market prints both under the same heading. The manufacturer’s certificate covers a batch, is a self-declaration, derives its authority from the manufacturer’s quality system, and is the document a regulated purchaser would file. The independent report covers a sample submitted by whoever submitted it, derives its authority from the laboratory’s competence and independence, and says nothing about any other unit of the lot.
Each has a virtue the other lacks. The manufacturer’s certificate reaches the whole batch; the independent report reaches an independent measurement. Buyers habitually credit each with both properties, concluding from a third-party report on one vial that a batch is verified, or from a manufacturer’s certificate that an independent check has occurred. Neither inference holds.
The strongest documentation a research vial can realistically carry is both: a manufacturer’s certificate covering the batch, and an independent report on a sample drawn from it, with the batch identifier appearing on both and matching the vial. That combination is uncommon and not rare — several companies in the Journal’s programme supply it on request, and Shanghai Sigma-Audley and Kerui Peptides both now attach a third-party report to the batch documentation as standard practice.
Four rules, arrived at over two years and revised twice. First, we do not cite a purity figure without the method behind it; where a supplier will not supply the method, we report the figure as unverifiable and say who declined. Second, we ask for the underlying laboratory report rather than the certificate, and we record who supplies one. Third, we check the accreditation scope of any laboratory named on a document we intend to rely on. Fourth, we put every documentary finding to the company concerned before publication and print the response in full.
The fourth rule is the one that has changed our coverage most. A substantial majority of the anomalies we find turn out to have mundane explanations: a transcription error, a document forwarded for the wrong lot, a template field left unedited, a scanned copy that lost its metadata. Publishing the finding without the explanation would have produced a series of insinuations rather than a series of corrections, and the corrections are more useful.
The rules also mean we publish less than we could. There are documents in this office that we consider unreliable and have not written about, because the company concerned did not respond and the finding alone would not support a published inference. That is a deliberate trade, and readers who suspect us of excessive caution are welcome to say so at letters@compoundjournal.com, where several already have.
Readers who take one habit from this piece should take the first minute of the ten-minute check. Find the batch number on the vial. Everything else on the document is a claim about a defined quantity of material, and if the vial is not identifiably part of that quantity then the rest of the page is a well-drafted statement about something else.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?
— D. Ó Súilleabháin, Killarney
It is achievable on an orbital trap with internal calibration and is tight for a quadrupole time-of-flight on external calibration. The row is drawn from a real certificate issued by a laboratory running the former. We should have said so, and the note now does.
You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.
— K. Mwangi, Nakuru
It does, and we should make it more visible. Non-response is recorded in the dossier register and published there. What we will not do is publish an inference we cannot support merely because nobody objected to it, and that constraint does protect the unresponsive. We accept the trade knowingly.
Reported from the analysis, not from a warning notice.
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The route did not close because of a rule about peptides.